Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
K-877-ER and CSG452 in NASH
NCT05327127Phase 2Completed
- Start
- Nov 2022
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of pemafibrate, tofogliflozin in Nonalcoholic steatohepatitis (NASH). Started Nov 2022; status: completed.
02
Drugs
pemafibratetofogliflozin
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT05327127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327127.